155 related articles for article (PubMed ID: 18048811)
1. p53: it has it all, but will it make it to the clinic as a marker in bladder cancer?
Real FX
J Clin Oncol; 2007 Dec; 25(34):5341-4. PubMed ID: 18048811
[No Abstract] [Full Text] [Related]
2. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer.
George B; Datar RH; Wu L; Cai J; Patten N; Beil SJ; Groshen S; Stein J; Skinner D; Jones PA; Cote RJ
J Clin Oncol; 2007 Dec; 25(34):5352-8. PubMed ID: 18048815
[TBL] [Abstract][Full Text] [Related]
3. Tumour diagnosis.
Hall PA; Dowell SP; Lane DP
Nature; 1994 Jun; 369(6483):701. PubMed ID: 8008057
[No Abstract] [Full Text] [Related]
4. Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer.
Cormio L; Tolve I; Annese P; Saracino A; Zamparese R; Sanguedolce F; Bufo P; Battaglia M; Selvaggi FP; Carrieri G
Anticancer Res; 2009 Oct; 29(10):4201-4. PubMed ID: 19846973
[TBL] [Abstract][Full Text] [Related]
5. p53 and p53-regulated genes in bladder cancer.
Crew JP; Jones A
BJU Int; 1999 Mar; 83(4):529-30. PubMed ID: 10210595
[No Abstract] [Full Text] [Related]
6. Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder.
Liu L; Zhu D; Gao R; Guo H
Urol Int; 2008; 81(1):72-6. PubMed ID: 18645275
[TBL] [Abstract][Full Text] [Related]
7. p53: from clinical significance to significance in the clinic?
Hall AR; Braithwaite A
N Z Med J; 1997 Sep; 110(1052):347-8. PubMed ID: 9364174
[No Abstract] [Full Text] [Related]
8. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
9. p53 as a potential target in cancer therapy.
Ozturk M; Ponchel F; Puisieux A
Bone Marrow Transplant; 1992; 9 Suppl 1():164-70. PubMed ID: 1504661
[No Abstract] [Full Text] [Related]
10. Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer.
Ecke TH; Schlechte HH; Gunia S; Lenk SV; Loening SA
Urol Oncol; 2008; 26(5):470-3. PubMed ID: 18367114
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of the p53 tumor-suppressor gene.
Bokemeyer C; Kuczyk MA; Sehrt J
N Engl J Med; 1994 Mar; 330(12):865. PubMed ID: 8114849
[No Abstract] [Full Text] [Related]
12. Molecular staging of bladder cancer.
Mitra AP; Datar RH; Cote RJ
BJU Int; 2005 Jul; 96(1):7-12. PubMed ID: 15963111
[TBL] [Abstract][Full Text] [Related]
13. p53 and RB: simple interesting correlates or tumor markers of critical predictive nature?
Cordon-Cardo C
J Clin Oncol; 2004 Mar; 22(6):975-7. PubMed ID: 14981108
[No Abstract] [Full Text] [Related]
14. TP53 gene mutations as an independent marker for urinary bladder cancer progression.
Ecke TH; Sachs MD; Lenk SV; Loening SA; Schlechte HH
Int J Mol Med; 2008 May; 21(5):655-61. PubMed ID: 18425359
[TBL] [Abstract][Full Text] [Related]
15. Re: Paula M.J. Moonen, Judith M.J.E. Bakkers, Lambertus A.L.M. Kiemenay et al. Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol 2007;52:464-9.
Cai T; Mazzoli S; Mondaini N; Bartoletti R
Eur Urol; 2008 Apr; 53(4):858-9; author reply 859. PubMed ID: 17920185
[No Abstract] [Full Text] [Related]
16. [Non-invasive molecular detection of bladder cancer].
Hatachmi S
Harefuah; 2009 Jan; 148(1):66-9, 86. PubMed ID: 19320394
[TBL] [Abstract][Full Text] [Related]
17. DBC2 gene is silenced by promoter methylation in bladder cancer.
Shi Y; Chen JY; Yang J; Li B; Chen ZH; Xiao CG
Urol Oncol; 2008; 26(5):465-9. PubMed ID: 18640857
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic biomarkers in urothelial bladder cancer.
Kim WJ; Kim YJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):259-69. PubMed ID: 19379084
[TBL] [Abstract][Full Text] [Related]
19. Gene signatures for risk-adapted treatment of bladder cancer.
Ørntoft TF; Dyrskjøt L
Scand J Urol Nephrol Suppl; 2008 Sep; (218):166-74. PubMed ID: 18815931
[TBL] [Abstract][Full Text] [Related]
20. [Re: "Usefulness of p53 in the clinical management of bladder tumors", by S. Bernardini, E. Chabannes, H. Bittard. Prog. Urol., (2001), 11, 201-208].
Pfister C
Prog Urol; 2001 Sep; 11(4):761. PubMed ID: 11761706
[No Abstract] [Full Text] [Related]
[Next] [New Search]
